Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O8KX
|
|||
| Former ID |
DNCL002048
|
|||
| Drug Name |
Reslizumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Severe asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Approved | [1] | |
| Eosinophilic asthma [ICD-11: CB02.0; ICD-9: 493] | Phase 3 | [2], [3] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [4], [5], [6], [7], [8] | ||
| Company |
Teva
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091). | |||
| REF 3 | ClinicalTrials.gov (NCT01290887) Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma. U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma | |||
| REF 5 | ClinicalTrials.gov (NCT00538434) Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | |||
| REF 6 | ClinicalTrials.gov (NCT03074942) Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab | |||
| REF 7 | ClinicalTrials.gov (NCT02947945) Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study | |||
| REF 8 | ClinicalTrials.gov (NCT01111305) Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis | |||
| REF 9 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.